select a format

Single User License
USD 3500 INR 224490
Site License
USD 7000 INR 448980
Corporate User License
USD 10500 INR 673470

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Cytotoxic T-Lymphocyte Protein 4 CTLA-4 or CD152-Pipeline Review, H1 2016

Cytotoxic T-Lymphocyte Protein 4 CTLA-4 or CD152-Pipeline Review, H1 2016


  • Products Id :- GMDHC0058TDB
  • |
  • Pages: 62
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Pipeline Review, H1 2016', provides in depth analysis on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted pipeline therapeutics.

The report provides comprehensive information on the Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)

The report reviews Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics and enlists all their major and minor projects

The report assesses Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Overview 8

Therapeutics Development 9

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Products under Development by Stage of Development 9

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Products under Development by Therapy Area 10

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Products under Development by Indication 11

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Products under Development by Companies 15

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Products under Development by Universities/Institutes 17

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Companies Involved in Therapeutics Development 26

Aduro BioTech, Inc. 26

Agenus, Inc. 27

Alligator Bioscience AB 28

AlphaMab Co., Ltd 29

CytomX Therapeutics, Inc. 30

Hanmi Pharmaceuticals, Co. Ltd. 31

JHL Biotech, Inc. 32

Lytix Biopharma AS 33

Novartis AG 34

OncoImmune, Inc. 35

Pfizer Inc. 36

Premier Biomedical Inc. 37

PsiOxus Therapeutics Limited 38

Sutro Biopharma, Inc. 39

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Drug Profiles 40

ADC-1015-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

AGEN-2041-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Anti-CTLA4 + LTX-315-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Biologic to Antagonize CTLA4 for Solid Tumor-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Biologics to Target CTLA4 and TNF Alpha-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

JMW-3B3-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

KN-044-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Monoclonal Antibody Conjugate to Target CTLA-4 for Oncology-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Monoclonal Antibody to Antagonize CTLA-4 for Oncology-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Monoclonal Antibody to Antagonize CTLA4 for Breast Cancer-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Monoclonal Antibody to Antagonize CTLA4 for Oncology-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Monoclonal Antibody to Antagonize CTLA4 for Oncology-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Monoclonal Antibody to Target GLUT2 and CTLA4 for Type 1 Diabetes-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Monocloncal Antibody to Inhibit CTLA-4 for Oncology-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ONC-392-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule to Target CTLA4 and IFNGR for RRMS-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Dormant Projects 59

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)-Featured News & Press Releases 60

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Figures

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Top 10 Indication, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Mechanism of Actions, H1 2016 20

Number of Products by Stage and Mechanism of Actions, H1 2016 20

Number of Products by Routes of Administration, H1 2016 22

Number of Products by Stage and Routes of Administration, H1 2016 22

Number of Products by Molecule Types, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 24

List of Tables

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Comparative Analysis by Unknown Stage Development, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Products under Investigation by Universities/Institutes, H1 2016 18

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 21

Number of Products by Stage and Route of Administration, H1 2016 23

Number of Products by Stage and Molecule Type, H1 2016 25

Pipeline by Aduro BioTech, Inc., H1 2016 26

Pipeline by Agenus, Inc., H1 2016 27

Pipeline by Alligator Bioscience AB, H1 2016 28

Pipeline by AlphaMab Co., Ltd, H1 2016 29

Pipeline by CytomX Therapeutics, Inc., H1 2016 30

Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 31

Pipeline by JHL Biotech, Inc., H1 2016 32

Pipeline by Lytix Biopharma AS, H1 2016 33

Pipeline by Novartis AG, H1 2016 34

Pipeline by OncoImmune, Inc., H1 2016 35

Pipeline by Pfizer Inc., H1 2016 36

Pipeline by Premier Biomedical Inc., H1 2016 37

Pipeline by PsiOxus Therapeutics Limited, H1 2016 38

Pipeline by Sutro Biopharma, Inc., H1 2016 39

Dormant Projects, H1 2016 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech, Inc.

Agenus, Inc.

Alligator Bioscience AB

AlphaMab Co., Ltd

CytomX Therapeutics, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

JHL Biotech, Inc.

Lytix Biopharma AS

Novartis AG

OncoImmune, Inc.

Pfizer Inc.

Premier Biomedical Inc.

PsiOxus Therapeutics Limited

Sutro Biopharma, Inc.

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Therapeutic Products under Development, Key Players in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Therapeutics, Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Pipeline Overview, Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Pipeline, Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com